https://www.selleckchem.com/pr....oducts/adenosine-cyc
48 [95%CI 0.30-0.77] vs clopidogrel; HR 0.32 [95%CI 0.20-0.52] vs ticagrelor; HR 0.36 [95%CI 0.24-0.55] vs standard-dose prasugrel; and HR 0.40 [95%CI 0.22-0.75] vs low-dose prasugrel) without negatively affecting primary efficacy outcomes. There were no significant differences in ischemic or bleeding outcomes between de-escalation to clopidogrel or low-dose prasugrel. Compared with other established uses of DAPT, de-escalation was the most effective strategy for ACS treatment, resulting in fewer bleeding events without
Like
Comment
Share
